Remed Pharmaceuticals has experienced a significant boost in sales following the acquisition of a majority stake by MOHS Analytics, Inc. in the latter part of 2024. The company’s sales escalated in the first half of 2025, surpassing targets by 88% and exhibiting a 35% increase compared to the same period in 2024. Particularly noteworthy was the remarkable growth in the quarter ending June 2024, with sales exceeding targets by 102% and showing a 70% rise from the preceding year.
The Mercury Drug chain witnessed outstanding sales growth, doubling its figures from the corresponding period in the previous year. This surge in sales can be attributed to the expansion of Remed Pharmaceuticals’ distribution network in major key accounts and national chain drugstores. The number of outlets surged from 2,500 to 4,000 nationwide, enhancing accessibility and brand visibility. Notably, the company has been focused on securing at least an 80% presence for its “Must Carry” brands in prominent drugstore chains like Mercury, Watsons, and Generika, resulting in the inclusion of five new products with seven SKUs in these key locations.
MOHS’s CEO, Michael B. Hortaleza, emphasized the importance of trust-building with partners, product innovation, and enhancing healthcare accessibility through digitalization. Recognizing the disruptive potential of Artificial Intelligence, the company is leveraging product innovation and digital tools to drive growth and operational efficiency. The strategic vision for 2031 aligns with founder Remedios A. Rivera’s aspiration for a forward-thinking, research-centric company responsive to global health trends.
Remed Pharmaceuticals’ growth spanned across all four therapeutic categories, including Mouth Antifungal, Respicare, Gastrocare, and Vita lines. A concerted marketing strategy was implemented to ensure equitable promotion across these categories and drive prescription generation through a digital platform used by medical representatives. The company’s marketing initiatives focus on raising awareness among healthcare professionals and supporting over-the-counter products with above-the-line promotions.
Despite rapid growth and substantial investments, Remed Pharmaceuticals has maintained robust profitability and cost management. The company remains dedicated to its five-year roadmap, which mirrors the strategic direction set by the CEO. Amidst global economic challenges, the healthcare sector’s resilience is anticipated to drive sustained growth for the MOHS group. Looking ahead, Remed is implementing an 8-quarter product planning roadmap to introduce pediatric line extensions and pioneering offerings in new therapeutic domains, ensuring a continuous stream of innovative products.
MOHS Analytics’ acquisition of Remed Pharmaceuticals aligns with its strategy of vertical integration within the healthcare and wellness sector. This move is part of MOHS’s strategic roadmap to evolve into one of the Philippines’ leading fully integrated health and wellness enterprises.
Read more on manilastandard.net